Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dezocine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dezocine SCHEMBL29811203 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL29682715 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL12720257 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL9685743 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874182 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL3072 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL7781933 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL11874190 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL21081189 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 | |
| Dezocine SCHEMBL25583319 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1HSD11B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | disclosed |
| CN-116763931-A | Application of hydrochloric acid in preparation of preparation for improving stability and solubility of dezocine | 华创合成制药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-113679659-B | Dezote Xin Yuanwei gel composition and application thereof | 扬子江药业集团有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-113979875-B | Dezocine derivative crystal form A and preparation method and application thereof | 扬子江药业集团有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-113717568-B | Solvent-resistant mud yellow eye-filling ash and preparation method thereof | 广东优志新材料有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-111517969-B | Dezocine derivative and medical application thereof | 扬子江药业集团有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220117913-A1 | DEZOCINE DERIVATIVE AND MEDICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220072311-A1 | TREATMENT OF ADDICTION AND DEPENDENCY | TACA JR ARTURO C (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220047773-A1 | SELF-ELIMINATING COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2022-02-17 | — | — | US | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2004056337-A2 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS | PAIN THERAPEUTICS (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040024004-A1 | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists | SHERMAN BARRY M (US) | 2004-02-05 | — | — | US | disclosed |
| US-6683062-B2 | ATTACHING A BIOEFFECTING AGENT TO A SUBSTRATE WITH AN ANCHOR PROVIDED BY A LINKER COMPOUND WHICH ALSO FORMS A CLEAVABLE LINKAGE SO THAT THE DRUG HAS A SUSTAINED RELEASE; ANTI-THROMBOGENIC, -IMICROBIAL, -INFLAMMATORY AGENTS | SURFACE SOLUTIONS LABORATORIES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030191147-A1 | Opioid antagonist compositions and dosage forms | SHERMAN BARRY (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1284736-A2 | OPIOID ANTAGONIST COMPOSITIONS AND DOSAGE FORMS | Pain Therapeutics, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1280529-A2 | OPIOID ANTAGONIST CONTAINING COMPOSITION FOR ENHANCING THE POTENCY OR REDUCING ADVERSE SIDE EFFECTS OF OPIOID AGONISTS | Pain Therapeutics, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085257-A2 | OPIOID ANTAGONIST COMPOSITIONS AND DOSAGE FORMS | PAIN THERAPEUTICS, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085150-A2 | OPIOID ANTAGONIST CONTAINING COMPOSITION FOR ENCHACHING THE POTENCY OR REDUCING ADVERSE SIDE EFFECTS OFOPIOID AGONISTS | PAIN THERAPEUTICS, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-1067972-A1 | MULTICOMPONENT COMPLEX FOR USE WITH A SUBSTRATE | Surface Solutions Laboratories, Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999045970-A1 | MULTICOMPONENT COMPLEX FOR USE WITH A SUBSTRATE | SURFACE SOLUTIONS LABORATORIES, INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117913-A1 | DEZOCINE DERIVATIVE AND MEDICAL USE THEREOF | DAO, DDO, DEK | OPRM1 4/4885OPRK1 85/4885OPRD1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.